Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We employ our advanced, specialised process to create targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
Q96S44

UPID:
PRPK_HUMAN

ALTERNATIVE NAMES:
Atypical serine/threonine protein kinase TP53RK; Nori-2; TP53-regulating kinase; p53-related protein kinase

ALTERNATIVE UPACC:
Q96S44; B3KU44; Q3T977; Q5JZ01; Q6NZ60; Q96FM7; Q9NQE6

BACKGROUND:
The EKC/KEOPS complex subunit TP53RK, known for its alternative names such as TP53-regulating kinase, is pivotal in cellular biology. It ensures the proper formation of a threonylcarbamoyl group on adenosine in tRNAs and activates the p53/TP53 protein, a critical pathway in cellular stress responses and tumor suppression.

THERAPEUTIC SIGNIFICANCE:
TP53RK's critical role in Galloway-Mowat syndrome 4, characterized by nephrotic syndrome and neurological abnormalities, underscores the importance of this protein in human health. Exploring TP53RK's functions offers promising avenues for developing novel therapeutic interventions for this and potentially other related conditions.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.